Safety Profiles and Proactive Therapy Management of First-Line Regimens in EGFR-Mutant NSCLC

Dr. Rodriguez addresses the wife’s concern about managing side effects at home. She frames the main toxicities of amivantamab in two categories. The first is infusion-related reactions (IRRs), which are reduced with the subcutaneous formulation. The second is the combination of cutaneous toxicity (rash, paronychia) and venous thromboembolism (VTE), which requires structured prophylaxis and a proactive plan for at-home management. Weekly clinic visits during cycle 1 support that monitoring even with the SC formulation.

For VTE prophylaxis, Dr. Rodriguez initiates anticoagulation at treatment start and continues it for approximately 3 to 4 months, noting that anticoagulation is safe in patients with brain metastases provided disease is controlled and there is no intracranial hemorrhage. The PALOMA-3 mandatory-prophylaxis approach reduced VTE rates to approximately 7%, in line with the baseline lung-cancer population. For cutaneous toxicity, she counsels patients to have antibiotics on hand from day 1, use sun protection, apply topical antibiotics, and use a chlorhexidine solution on the nails and toes to prevent paronychia. The COCOON regimen reduced grade ≥2 dermatologic adverse events from 75% to 42%; it includes minocycline 100 mg twice daily (or doxycycline) for the first 12 weeks, clindamycin 1% lotion to the scalp through week 52, daily chlorhexidine to the nails, and a daily ceramide-based moisturizer.

She compares grade ≥3 adverse event rates: approximately 52% with osimertinib monotherapy and up to 80% with amivantamab plus lazertinib in the original IV-era MARIPOSA cohort (where not all patients received prophylaxis); the ongoing COCOON study is evaluating prophylaxis-on-protocol with the SC formulation. For FLAURA2, grade ≥3 events were approximately 70% versus 34% with monotherapy, driven by hematologic toxicity (cytopenias, anemia) and gastrointestinal effects. Importantly, amivantamab-related adverse events cluster in the first 4 months and decline thereafter, and patients who require dose reductions still derive benefit; 38% of MARIPOSA patients remained on amivantamab plus lazertinib at the clinical cutoff versus 28% on osimertinib.

In the next episode, “Subcutaneous Amivantamab and Q4W Dosing for First-Line EGFR-Mutant NSCLC,” Dr. Rodriguez translates administration logistics into what they mean for Mr. Smith and his care partner.